Glottic Cancer Treatment Market

Glottic Cancer Treatment Market

The global cancer treatment demand is likely to grow at around 7% to 7.8% CAGR during the forecast period from 2022 and 2032. Growth in the market is primarily driven by increasing prevalence of laryngeal cancer and growing popularity of effective treatments like radiotherapy and chemotherapy.

Report Attribute	Details
Glottic Cancer Treatment Market Projected Growth Rate (2022-2032)	7% - 7.8% CAGR

Glottic cancer is a type of cancer that forms in tissues of the larynx or vocal cords. Presence of this cancer causes various symptoms ranging from mild ones like a persistent cough, hoarseness, sore throat and abnormal lump formation to severe ones like swallowing and breathing difficulties. If glottic cancer remains untreated it can spread to other sections of the neck and lungs and can thus be extremely fatal. As a result, demand for glottic cancer treatment is witnessing a huge upsurge and the trend is likely to continue in the future.

Various treatment options such as non-surgical therapy, radiation, chemotherapy, and combinational therapy are available for minimizing the symptoms and treating glottic cancer depending on the stage of the cancer.

For early stages of glottic cancer, treatment options like radiation and endoscopic excision are highly suitable, while for moderate to advanced stages of glottic cancer, treatment with combinational therapy is highly recommended. Similarly for people with last stages or people who do not respond to radiation therapy and chemotherapy, surgery-based treatment is the last option.

Which Factors are Spurring the Growth of Glottic Cancer Treatment Market?

The robust expansion of glottic cancer treatment market is attributable to rising prevalence of glottic cancer worldwide, growing health awareness among people, advancements in cancer research, and increasing government initiatives.

Rise in the number of larynx cancer cases due to excessive smoking and drinking is perhaps one of the major factors accelerating the growth of glottic cancer treatment market. As per the Global Cancer Observatory (GCO), there were around 184615 new cases of larynx cancer reported in 2020 worldwide. About 60% of the laryngeal cancers start in the area containing the vocal cords (glottis).

Similarly, growing awareness among people regarding glottic cancer, its symptoms and treatment will continue to act as a catalyst for the growth of glottic cancer treatment market during the assessment period.

In addition to this, rising geriatric population along with growing popularity of radiation therapy and chemotherapy for their effectiveness will further boost the growth of glottic cancer treatment market in future. It has been observed that most of people diagnosed with laryngeal cancer are 55 or older (American Cancer Society).

What are the Challenges Faced by the Glottic Cancer Treatment Market?

Despite its optimistic stance, glottic cancer treatment market is facing various challenges that are restraining its growth. Some of these factors are the high cost of glottic cancer treatments, side effects associated with treatments like radiation and chemotherapy, and lack of awareness about the availability of various glottic cancer treatments across some emerging nations.

Why is North America Considered as a Prominent Market for Glottic Cancer Treatment?

North America was the leading market for glottic cancer treatment in 2022 and is projected to retain its dominance during the assessment period, owing to the rising prevalence of laryngeal cancer, high level of awareness among people regarding cancer and its treatment, increase in smoking rates, and heavy presence of leading market players.

The United States remains the leading market for glottic cancer treatment across North America due to high patient pool, rise in smoking and drinking habits, and advancements in cancer research.

According to the American Cancer Society, there will be around 12470 new cases of laryngeal cancer across the United States in 2022 while about 3820 people will die from it. This will generate lucrative growth avenues within the glottis cancer treatment market across the country.

Similarly, rising geriatric population along with increasing governmental support and introduction of reimbursement policies will further expand the size of glottic cancer treatment market across North America during the forecast period.

What is the Growth Projection for Europe Market?

According to Future Market Insights, Europe will continue to remain the second most lucrative market for glottic cancer treatments, growing at a healthy CAGR over the forecast period. Growth in the market is driven by rising incidence of glottic cancer, increase in smoking rates, growing health awareness among people, and large presence of end user verticals.

Demand for glottic cancer treatments is particularly high across countries like the U.K., Netherlands, and Germany due to availability of better cancer specialists, presence of well-established medical industry, and growing medical tourism.

Market Competition

Some of the key participants present in the global glottic cancer treatment market include Novartis, Eli Lilly and Company, Merck & Co., Inc, Cipla Ltd., F. Hoffmann-la Roche AG, Amgen Inc., Biocon, Bristol-Myers Squibb, Engeneic Ltd, Pfizer Inc., Celgene Corporation, and Teva Pharmaceutical Industries Ltd. among others.

The presence of these large numbers of participants makes the global glottic cancer treatment market highly competitive in nature. Leading players are adopting various growth strategies such as partnerships, mergers, acquisitions, and collaborations to gain a competitive edge in the market and expand their global footprint. Besides this, they are investing heavily in research and development activities to advance in cancer treatments.

Scope of Report

Report Attribute	Details
Growth Rate	CAGR of 7% - 7.8% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2015-2020
Forecast Period	2022-2032
Quantitative Units	Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Treatment Type End User Region
Regions Covered	North America Latin America Western Europe Eastern Europe APEJ Japan Middle East and Africa
Key Countries Profiled	U.S Canada Brazil Argentina Germany U.K France Spain Italy Nordics BENELUX Australia & New Zealand China India ASEAN GCC South Africa
Key Companies Profiled	Novartis Eli Lilly and Company Merck & Co., Inc Cipla Ltd. Amgen Inc. Biocon Bristol-Myers Squibb Engeneic Ltd Pfizer Inc. Celgene Corporation F. Hoffmann-la Roche AG and Teva Pharmaceutical Industries Ltd.
Customization	Available Upon Request

Key Segments Profiled in the Glottic Cancer Treatment Industry Survey

By Treatment Type:

• Non-Surgical Therapy
• Radiation
• Chemotherapy
• Combinational Therapy (Radiotherapy + Chemotherapy)
• Surgical Therapy
• Endoscopic Laser Surgery
• Cordectomy
• Partial Laryngectomy

By End User:

• Hospital Laboratories
• Ambulatory Surgical Centers
• Physician Office
• Others

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• Japan
• Middle East & Africa